0001104659-21-084261.txt : 20210622 0001104659-21-084261.hdr.sgml : 20210622 20210622182647 ACCESSION NUMBER: 0001104659-21-084261 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210618 FILED AS OF DATE: 20210622 DATE AS OF CHANGE: 20210622 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: WEISS MICHAEL S CENTRAL INDEX KEY: 0001038977 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-32639 FILM NUMBER: 211036654 MAIL ADDRESS: STREET 1: 750 LEXINGTON AVE CITY: NEW YORK STATE: NY ZIP: 10022 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: TG THERAPEUTICS, INC. CENTRAL INDEX KEY: 0001001316 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 363898269 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2 GANSEVOORT STREET, 9TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10014 BUSINESS PHONE: (212) 554-4484 MAIL ADDRESS: STREET 1: 2 GANSEVOORT STREET, 9TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10014 FORMER COMPANY: FORMER CONFORMED NAME: MANHATTAN PHARMACEUTICALS INC DATE OF NAME CHANGE: 20030310 FORMER COMPANY: FORMER CONFORMED NAME: ATLANTIC TECHNOLOGY VENTURES INC DATE OF NAME CHANGE: 20000330 FORMER COMPANY: FORMER CONFORMED NAME: ATLANTIC PHARMACEUTICALS INC DATE OF NAME CHANGE: 19960703 4 1 tm2120405-6_4seq1.xml OWNERSHIP DOCUMENT X0306 4 2021-06-18 0 0001001316 TG THERAPEUTICS, INC. TGTX 0001038977 WEISS MICHAEL S 2 GANSEVOORT STREET, 9TH FLOOR NEW YORK NY 10014 1 1 0 0 CEO and President COMMON STOCK 2021-06-18 4 A 0 1080770 0 A 14148852 D Reflects the final annual grant of restricted stock pursuant to the Strategic Advisory Agreement with Caribe BioAdvisors, LLC, pursuant to which Mr. Weiss provided the services of Chairman of the Board and Executive Chairman. The restricted shares will vest on the date that the Company's Market Capitalization is $500 million greater than the Market Capitalization on the date of grant as measured within a five-year timeframe, but in no event before December 1, 2022. Included in Mr. Weiss' beneficial ownership are 4,909,355 shares of Common Stock issued to Opus Point Partners, LLC, of which Mr. Weiss is a principal and beneficially owns a 50% interest. /s/ Michael S. Weiss 2021-06-22